Skip to main content
AAN.com

Abstract

A 66-year-old man, with a history of Wolff-Parkinson-White syndrome, coronary artery disease, left partial colectomy for polyps, and alcohol abuse (≈50 g/d), attempted suicide by ingestion of commercially available glyphosate (Round-Up, ≈200 mL). He was admitted to the emergency ward for monitoring and hyperhydration. First clinical and biological workup and gastric endoscopic examinations were normal.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
Jack CR, Petersen RC, Xu Y, et al. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology 2000;55:484–489.
2.
Zheng Q, Yin J, Zhu L, Jiao L, Xu Z. Reversible parkinsonism induced by acute exposure glyphosate. Parkinsonism Relat Disord 2018;50:121.
3.
Malhotra RC, Ghia DK, Cordato DJ, Beran RG. Glyphosate-surfactant herbicide-induced reversible encephalopathy. J Clin Neurosci 2010;17:1472–1473.
4.
Nishiyori Y, Nishida M, Shioda K, Suda S, Kato S. Unilateral hippocampal infarction associated with an attempted suicide: a case report. J Med Case Rep 2014;8:219.
5.
Sánchez-Santed F, Colomina MT, Herrero Hernández E. Organophosphate pesticide exposure and neurodegeneration. Cortex 2016;74:417–426.
6.
Cattani D, de Liz Oliveira Cavalli VL, Heinz Rieg CE, et al. Mechanisms underlying the neurotoxicity induced by glyphosate-based herbicide in immature rat hippocampus: involvement of glutamate excitotoxicity. Toxicology 2014;320:34–45.
7.
Gui Y, Fan X, Wang H, Wang G, Chen S. Glyphosate induced cell death through apoptotic and autophagic mechanisms. Neurotoxicol Teratol 2012;34:344–349.

Information & Authors

Information

Published In

Neurology®
Volume 92Number 11March 12, 2019
Pages: 534-536
PubMed: 30737339

Publication History

Received: August 31, 2018
Accepted: November 29, 2018
Published online: February 8, 2019
Published in print: March 12, 2019

Permissions

Request permissions for this article.

Disclosure

The authors report no disclosures relevant to the manuscript. Go to Neurology.org/N for full disclosures.

Study Funding

No targeted funding reported.

Authors

Affiliations & Disclosures

Vincent Planche, MD, PhD https://orcid.org/0000-0003-3713-227X
From the Institut des Maladies Neurodégénératives (V.P., S.V., N.A., M.B., F.T.), CNRS UMR 5293; Université de Bordeaux (V.P., S.V., N.A., M.B., T.T., F.T.); CHU de Bordeaux (V.P., S.V., N.A., M.B., T.T., F.T.); and Neurocentre Magendie (T.T.), INSERM U1215, Bordeaux, France.
Disclosure
Scientific Advisory Boards:
1.
Merck-Sereno
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Biogen, Merck-Sereno, ARSEP Foundation
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Sylvain Vergnet, MD
From the Institut des Maladies Neurodégénératives (V.P., S.V., N.A., M.B., F.T.), CNRS UMR 5293; Université de Bordeaux (V.P., S.V., N.A., M.B., T.T., F.T.); CHU de Bordeaux (V.P., S.V., N.A., M.B., T.T., F.T.); and Neurocentre Magendie (T.T.), INSERM U1215, Bordeaux, France.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Nicolas Auzou, PhD
From the Institut des Maladies Neurodégénératives (V.P., S.V., N.A., M.B., F.T.), CNRS UMR 5293; Université de Bordeaux (V.P., S.V., N.A., M.B., T.T., F.T.); CHU de Bordeaux (V.P., S.V., N.A., M.B., T.T., F.T.); and Neurocentre Magendie (T.T.), INSERM U1215, Bordeaux, France.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Marie Bonnet, MSc
From the Institut des Maladies Neurodégénératives (V.P., S.V., N.A., M.B., F.T.), CNRS UMR 5293; Université de Bordeaux (V.P., S.V., N.A., M.B., T.T., F.T.); CHU de Bordeaux (V.P., S.V., N.A., M.B., T.T., F.T.); and Neurocentre Magendie (T.T.), INSERM U1215, Bordeaux, France.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Thomas Tourdias, MD, PhD
From the Institut des Maladies Neurodégénératives (V.P., S.V., N.A., M.B., F.T.), CNRS UMR 5293; Université de Bordeaux (V.P., S.V., N.A., M.B., T.T., F.T.); CHU de Bordeaux (V.P., S.V., N.A., M.B., T.T., F.T.); and Neurocentre Magendie (T.T.), INSERM U1215, Bordeaux, France.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
Grants from the French Agence Nationale de la Recherche within the context of the Investments for the Future program referenced ANR-10-LABX-57 named TRAIL and ANR-10-LABX-43 named BRAIN.
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Grants from ARSEP foundation ?Fondation pour l'aide a la recherche sur la scl?rose en plaques?.
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
François Tison, MD, PhD
From the Institut des Maladies Neurodégénératives (V.P., S.V., N.A., M.B., F.T.), CNRS UMR 5293; Université de Bordeaux (V.P., S.V., N.A., M.B., T.T., F.T.); CHU de Bordeaux (V.P., S.V., N.A., M.B., T.T., F.T.); and Neurocentre Magendie (T.T.), INSERM U1215, Bordeaux, France.

Notes

Correspondence Dr. Planche [email protected]
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

Author Contributions

V. Planche, S. Vergnet, and F. Tison: clinical diagnostic and patient follow-up, interpretation of results, drafting/revising the manuscript. N. Auzou and M. Bonnet: execution and interpretation of neuropsychological tests, revising the manuscript. T. Tourdias: execution and interpretation of imaging studies, revising the manuscript.

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. The role of alcohol use in pesticide suicide and self-harm: a scoping review, Social Psychiatry and Psychiatric Epidemiology, (2023).https://doi.org/10.1007/s00127-023-02526-9
    Crossref
  2. Urinary concentrations of neonicotinoid insecticides were related to renal tubular dysfunction and neuropsychological complaints in Dry-zone of Sri Lanka, Scientific Reports, 11, 1, (2021).https://doi.org/10.1038/s41598-021-01732-2
    Crossref
  3. Analytical strategies to measure herbicide active ingredients and their metabolites, Herbicides, (113-141), (2021).https://doi.org/10.1016/B978-0-12-823674-1.00001-8
    Crossref
  4. Glyphosate exposure induces synaptic impairment in hippocampal neurons and cognitive deficits in developing rats, Archives of Toxicology, 95, 6, (2137-2150), (2021).https://doi.org/10.1007/s00204-021-03046-8
    Crossref
  5. Transient glyphosate encephalopathy due to a suicide attempt, Neuropsychopharmacology Reports, 41, 3, (444-447), (2021).https://doi.org/10.1002/npr2.12201
    Crossref
  6. Translational imaging in toxicology, Current Opinion in Toxicology, 23-24, (29-38), (2020).https://doi.org/10.1016/j.cotox.2020.03.006
    Crossref
Loading...

View Options

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

Purchase this article to get full access to it.

Purchase Access, $39 for 24hr of access

View options

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share